RT Journal Article SR Electronic T1 2014 Update of the Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada Treatment Recommendations for the Management of Spondyloarthritis. Part I: Principles of the Management of Spondyloarthritis in Canada JF The Journal of Rheumatology JO J Rheumatol FD The Journal of Rheumatology SP jrheum.141000 DO 10.3899/jrheum.141000 A1 Sherry Rohekar A1 Jon Chan A1 Shirley M.L. Tse A1 Nigil Haroon A1 Vinod Chandran A1 Louis Bessette A1 Dianne Mosher A1 Cathy Flanagan A1 Kevin J. Keen A1 Karen Adams A1 Michael Mallinson A1 Carter Thorne A1 Proton Rahman A1 Dafna D. Gladman A1 Robert D. Inman YR 2015 UL http://www.jrheum.org/content/early/2015/02/10/jrheum.141000.abstract AB Objective The Canadian Rheumatology Association (CRA) and the Spondyloarthritis Research Consortium of Canada (SPARCC) have collaborated to update the recommendations for the management of spondyloarthritis (SpA). Methods A working group was assembled and consisted of the SPARCC executive committee, rheumatologist leaders from SPARCC collaborating sites, Canadian rheumatologists from across the country with an interest in SpA (both academic and community), a rheumatology trainee with an interest in SpA, an epidemiologist/health services researcher, a member of the CRA executive, a member of the CRA therapeutics committee, and a patient representative from the Canadian Spondylitis Association. An extensive review was conducted of literature published from 2007 to 2014 involving the management of SpA. The working group created draft recommendations using multiple rounds of Web-based surveys and an in-person conference. A survey was sent to the membership of the CRA to obtain an extended review that was used to finalize the recommendations. Results Guidelines for the management of SpA were created. Part I focuses on the principles of management of SpA in Canada and includes 6 general management principles, 5 ethical considerations, target groups for treatment recommendations, 2 wait time recommendations, and recommendations for disease monitoring. Also included are 6 modifications for application to juvenile SpA. Conclusion These recommendations were developed based on current literature and applied to a Canadian healthcare context. It is hoped that the implementation of these recommendations will promote best practices in the treatment of SpA.